Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 15/20 | 1.00 |
| ▸ | HDAC1 | Q13547 | 8/20 | 0.56 |
| ▸ | HDAC2 | Q92769 | 7/20 | 0.56 |
| ▸ | HDAC3 | O15379 | 6/20 | 0.56 |
| ▸ | HDAC7 | Q8WUI4 | 5/20 | 0.56 |
| ▸ | HDAC8 | Q9BY41 | 5/20 | 0.56 |
| ▸ | HDAC4 | P56524 | 4/20 | 0.56 |
| ▸ | HDAC10 | Q969S8 | 4/20 | 0.56 |
| ▸ | HDAC5 | Q9UQL6 | 4/20 | 0.56 |
| ▸ | HDAC11 | Q96DB2 | 3/20 | 0.56 |
| ▸ | HDAC9 | Q9UKV0 | 3/20 | 0.56 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.54 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2808670 | 0.76 | MEN1 (0.81) | HDAC6HDAC1HDAC2HDAC3HDAC7 | |
| SCHEMBL12672064 | 0.76 | MEN1 (0.81) | HDAC6HDAC1HDAC2HDAC3HDAC7 | |
| SCHEMBL1514510 | 0.75 | MEN1 (0.78) | MTNR1AMEN1KMT2A | |
| SCHEMBL2227669 | 0.74 | HDAC6 (1.00) | HDAC6HDAC1HDAC2HDAC3HDAC7 | |
| SCHEMBL1233057 | 0.74 | MEN1 (0.83) | HDAC6HDAC1HDAC2HDAC3HDAC7 | |
| SCHEMBL21691160 | 0.74 | HDAC6 (0.58) | HDAC6HDAC1HDAC2HDAC3HDAC7 | |
| SCHEMBL1305483 | 0.73 | MEN1 (0.67) | HDAC6HDAC1HDAC2HDAC3HDAC7 | |
| SCHEMBL1234076 | 0.73 | HDAC1 (0.69) | HDAC6HDAC1HDAC2HDAC3HDAC7 | |
| SCHEMBL1726877 | 0.71 | MEN1 (0.81) | MTNR1AMEN1KMT2A | |
| SCHEMBL2228145 | 0.71 | HDAC6 (1.00) | HDAC6HDAC1HDAC2HDAC3HDAC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110300134-A1 | REVERSE AMIDE COMPOUNDS AS PROTEIN DEACETYLASE INHIBITORS AND METHODS OF USE THEREOF | ACETYLON PHARMACEUTICALS (US) | 2011-12-08 | — | — | US | claimed |
| WO-2011091213-A2 | REVERSE AMIDE COMPOUNDS AS PROTEIN DEACETYLASE INHIBITORS AND METHODS OF USE THEREOF | ACETYLON PHARMACEUTICALS (US) | 2011-07-28 | — | — | WO | claimed |
| US-11617750-B2 | Reverse amide compounds as protein deacetylase inhibitors and methods of use thereof | ACETYLON PHARMACEUTICALS, INC. (US) | 2023-04-04 | — | — | US | disclosed |
| US-10648038-B2 | Biomarkers to identify patients that will respond to treatment and treating such patients | ACETYLON PHARMACEUTICALS, INC. (US) | 2020-05-12 | — | — | US | disclosed |
| US-20200030325-A1 | Reverse Amide Compounds As Protein Deacetylase Inhibitors And Methods Of Use Thereof | ACETYLON PHARMACEUTICALS, INC. | 2020-01-30 | — | — | US | disclosed |
| US-20200030325-A1 | Reverse Amide Compounds As Protein Deacetylase Inhibitors And Methods Of Use Thereof | ACETYLON PHARMACEUTICALS, INC. | 2020-01-30 | — | — | US | disclosed |
| EP-2839037-B1 | BIOMARKERS TO IDENTIFY PATIENTS THAT WILL RESPOND TO TREATMENT AND TREATING SUCH PATIENTS | ACETYLON PHARMACEUTICALS INC (US) | 2018-12-26 | — | — | EP | disclosed |
| US-20170327895-A1 | Biomarkers To Identify Patients That Will Respond To Treatment And Treating Such Patients | ACETYLON PHARMACEUTICALS, INC. | 2017-11-16 | — | — | US | disclosed |
| US-20170305866-A1 | Histone Deacetylase 6 Selective Inhibitors for the Treatment of Bone Disease | THE GENERAL HOSPITAL CORPORATION | 2017-10-26 | — | — | US | disclosed |
| US-9663825-B2 | Biomarkers to identify patients that will respond to treatment and treating such patients | ACETYLON PHARMACEUTICALS, INC. (US) | 2017-05-30 | — | — | US | disclosed |
| US-9512083-B2 | Histone deacetylase 6 selective inhibitors for the treatment of bone disease | THE GENERAL HOSPITAL CORPORATION (US) | 2016-12-06 | — | — | US | disclosed |
| US-20140378385-A1 | Histone Deacetylase 6 Selective Inhibitors for the Treatment of Bone Disease | THE GENERAL HOSPITAL CORPORATION (US) | 2014-12-25 | — | — | US | disclosed |
| US-20140142117-A1 | REVERSE AMIDE COMPOUNDS AS PROTEIN DEACETYLASE INHIBITORS AND METHODS OF USE THEREOF | ACETYLON PHARMACEUTICALS, INC. | 2014-05-22 | — | — | US | disclosed |
| US-20140142117-A1 | REVERSE AMIDE COMPOUNDS AS PROTEIN DEACETYLASE INHIBITORS AND METHODS OF USE THEREOF | ACETYLON PHARMACEUTICALS, INC. | 2014-05-22 | — | — | US | disclosed |
| WO-2013158984-A1 | BIOMARKERS TO IDENTIFY PATIENTS THAT WILL RESPOND TO TREATMENT AND TREATING SUCH PATIENTS | ACETYLON PHARMACEUTICALS, INC. (US) | 2013-10-24 | — | — | WO | disclosed |
| US-8394810-B2 | Reverse amide compounds as protein deacetylase inhibitors and methods of use thereof | ACETYLON PHARMACEUTICALS (US) | 2013-03-12 | — | — | US | disclosed |
| US-8394810-B2 | Reverse amide compounds as protein deacetylase inhibitors and methods of use thereof | ACETYLON PHARMACEUTICALS (US) | 2013-03-12 | — | — | US | disclosed |
| WO-2013013113-A2 | HISTONE DEACETYLASE 6 SELECTIVE INHIBITORS FOR THE TREATMENT OF BONE DISEASE | THE GENERAL HOSPITAL CORPORATION (US) | 2013-01-24 | — | — | WO | disclosed |
| US-20110300134-A1 | REVERSE AMIDE COMPOUNDS AS PROTEIN DEACETYLASE INHIBITORS AND METHODS OF USE THEREOF | ACETYLON PHARMACEUTICALS (US) | 2011-12-08 | — | — | US | disclosed |
| WO-2011091213-A2 | REVERSE AMIDE COMPOUNDS AS PROTEIN DEACETYLASE INHIBITORS AND METHODS OF USE THEREOF | ACETYLON PHARMACEUTICALS (US) | 2011-07-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110300134-A1 | REVERSE AMIDE COMPOUNDS AS PROTEIN DEACETYLASE INHIBITORS AND METHODS OF USE THEREOF | HDAC6, HDAC1, HDAC3 | HDAC6 1/4885HDAC1 2/4885HDAC2 7/4885 |
| US-20140378385-A1 | Histone Deacetylase 6 Selective Inhibitors for the Treatment of Bone Disease | HDAC1, HDAC6, HDAC9 | HDAC6 2/4885HDAC1 1/4885HDAC2 6/4885 |
| US-20200030325-A1 | Reverse Amide Compounds As Protein Deacetylase Inhibitors And Methods Of Use Thereof | HDAC6, HDAC1, HDAC3 | HDAC6 1/4885HDAC1 2/4885HDAC2 7/4885 |
| US-20170305866-A1 | Histone Deacetylase 6 Selective Inhibitors for the Treatment of Bone Disease | HDAC1, HDAC6, HDAC9 | HDAC6 2/4885HDAC1 1/4885HDAC2 6/4885 |
| US-20140142117-A1 | REVERSE AMIDE COMPOUNDS AS PROTEIN DEACETYLASE INHIBITORS AND METHODS OF USE THEREOF | HDAC6, HDAC1, HDAC3 | HDAC6 1/4885HDAC1 2/4885HDAC2 7/4885 |
| US-11617750-B2 | Reverse amide compounds as protein deacetylase inhibitors and methods of use thereof | HDAC6, HDAC1, HDAC3 | HDAC6 1/4885HDAC1 2/4885HDAC2 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.